Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

N/A

4(50.0%)

Phase 4

2(25.0%)

Phase 2

2(25.0%)

8Total

N/A(4)

Phase 4(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07382349Not ApplicableNot Yet Recruiting

A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease

Role: collaborator

NCT07046429Not ApplicableRecruiting

Affect of Melatonin on Sleep and Cognition in Cirrhosis

Role: collaborator

NCT04899115Phase 2Completed

VE303 for Treatment of Hepatic Encephalopathy (HE)

Role: collaborator

NCT04642391Completed

Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis

Role: collaborator

NCT04953143Not ApplicableCompleted

LiverPAL: A Pilot Study of Inpatient Palliative Care for Patients With Advanced Liver Disease

Role: collaborator

NCT03602976Phase 2Terminated

Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis

Role: collaborator

NCT04218695Phase 4Completed

Prophylactic Antibiotics in Admitted Cirrhotics

Role: collaborator

NCT03839082Not ApplicableCompleted

Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease

Role: collaborator

NCT00570960Phase 4Terminated

Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis

Role: collaborator

All 9 trials loaded